<!DOCTYPE html>

<html xmlns="http://www.w3.org/1999/xhtml">

<head>

<meta charset="utf-8" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />




<title>Vyriad</title>

<script src="site_libs/jquery-1.11.3/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/yeti.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-1.1/default.css" rel="stylesheet" />
<script src="site_libs/highlightjs-1.1/highlight.js"></script>

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs && document.readyState && document.readyState === "complete") {
   window.setTimeout(function() {
      hljs.initHighlighting();
   }, 0);
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
</style>


</head>

<body>

<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
  height: auto;
}
.tabbed-pane {
  padding-top: 12px;
}
button.code-folding-btn:focus {
  outline: none;
}
</style>


<style type="text/css">
/* padding for bootstrap navbar */
body {
  padding-top: 45px;
  padding-bottom: 40px;
}
/* offset scroll position for anchor links (for fixed navbar)  */
.section h1 {
  padding-top: 50px;
  margin-top: -50px;
}

.section h2 {
  padding-top: 50px;
  margin-top: -50px;
}
.section h3 {
  padding-top: 50px;
  margin-top: -50px;
}
.section h4 {
  padding-top: 50px;
  margin-top: -50px;
}
.section h5 {
  padding-top: 50px;
  margin-top: -50px;
}
.section h6 {
  padding-top: 50px;
  margin-top: -50px;
}
</style>

<script>
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.parent().addClass('active');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');
});
</script>


<div class="container-fluid main-container">

<!-- tabsets -->
<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});
</script>

<!-- code folding -->





<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Home</a>
    </div> 
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        
      </ul>
      <ul class="nav navbar-nav navbar-right">

        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Learn More About Each Company Here
     
    <span class="caret"></span>
  </a>
  
  <ul class="dropdown-menu" role="menu">

<style type="text/css">
          /*dropdown menu code start*/
          @media only screen and (min-width:769px) {
              .dropdown:hover .dropdown-menu {
                  display: block;
              }
              .dropdown-submenu {
                  position: relative !important;
              }

              .dropdown-submenu>.dropdown-menu {
                  top: 0 !important;
                  left: 100% !important;
                  margin-top: -6px !important;
                  margin-left: -1px !important;
                  border-radius: 0 !important;
              }

              .dropdown-submenu:hover>.dropdown-menu {
                  display: block !important;
              }

              .dropdown-submenu>a:after {
                  display: block;
                  content: "\f105";
                  font-family: 'FontAwesome';
                  margin-top: -15px;
                  right: 20px;
                  position: absolute;
                  font-weight: 300;
              }
              .customcaret{
                float: right;
              }
            }
          /*dropdown menu code start*/

         .navbar-default .navbar-nav > li > a {
            color: #535353;
            transition: all ease 0.5s;
            -webkit-transition: all ease 0.5s;
            -moz-transition: all ease 0.5s;
            font-size: 2em !important;
            text-transform: uppercase;
        }
        </style>
        
       
  <ul class="dropdown-submenu">
    <li>
      <a href="ADURO.html">Aduro Biotech</a>
    </li>
    
    <li>
      <a href="MERCK.html">Merck</a>
    </li>
    
    <li>
      <a href="SPRINGBANK.html">Spring bank pharmaceuticals</a>
    </li>
    
    <li>
      <a href="BMS.html">Bristol-Myers Squibb</a>
    </li>
    
    <li>
      <a href="Stinginn.html">StingInn</a>
    </li>
    
    <li>
      <a href="VYRIAD.html">Vyriad</a>
    </li>
    
    <li>
      <a href="CURADEV.html">Curadev</a>
    </li>
    
    <li>
      <a href="Mavupharma.html">Mavupharma</a>
    </li>
    
    <li>
      <a href="Synlogic.html">Synlogic</a>
    </li>
    
    <li>
      <a href="venn.html">Venn Therapeutics</a>
    </li>
    
    <li>
      <a href="IFM.html">IFM Therapeutics</a>
    </li>
    
    <li>
      <a href="iteo.html">iTeos Therapeutics</a>
    </li>
    
    <li>
      <a href="nimbus.html">NIMBUS Therapeutics</a>
    </li>
    
    <li>
      <a href="celgene.html">Celgene</a>
    </li>
    
    <li>
      <a href="sirenas.html">Sirenas</a>
    </li>
    
    <li>
      <a href="replimune.html">Replimune</a>
    </li>
    
  </ul>
  
</li>

      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div class="fluid-row" id="header">

<div class="fluid-row" id="header">



<h1 class="title toc-ignore">Vyriad</h1>

</div>


<style type="text/css">

body{ /* Normal  */
      font-size: 13px;
  }
}
h1.title {
  font-size: 28px;
  color: DarkBlue;
}
h1 { /* Header 1 */
  font-size: 20px;
  color: DarkBlue;
}
h2 { /* Header 2 */
    font-size: 16px;
  color: DarkBlue;
}

}
code.r{ /* Code block */
    font-size: 12px;
}
pre { /* Code block - determines code spacing between lines */
    font-size: 14px;
}
</style>
<p><br />
</p>
<div id="vyriad-potential-competitive-strength" class="section level1">
<h1><strong>Vyriad (potential competitive strength): </strong></h1>
<p>A new Biotech startup. August 2016, Vyriad signed a licensing agreement with Florida-based StingInn, LLC to use that company’s cyclic GMP-AMP Synthase STING (Stimulator of Interferon Genes) oncolytic virus technology with Vyriad’s oncolytic virotherapy product candidates for the treatment of advanced-stage cancers.</p>
<p>The company began as <code>Omnis Pharma</code>, but last year it merged with <code>Magnis Therapeutics</code> to form Vyriad. The two companies combined their pipelines to include Phase II product candidates in ovarian cancer and multiple myeloma, and Phase I programs in glioblastoma, mesothelioma, head and neck cancer, blood cancers, endometrial cancer, hematologic malignancies, and gastrointestinal cancer.</p>
<p>Vyriad also has seven pre-IND programs that include the pairing of oncolytic vaccines with other cancer immunotherapy approaches such as checkpoint inhibitors and standard chemotherapy treatments.</p>
</div>
<div id="latest-news-on-their-collaboration-with-other-big-companies-071818" class="section level1">
<h1><strong>Latest news on their collaboration with other big companies: (07/18/18)</strong></h1>
<p>They announced a collaboration agreement with <code>Merck KGaA</code>, <code>Darmstadt</code>, <code>Germany</code>, and <code>Pfizer</code> to expand its ongoing Phase 1 clinical trial program in solid tumors to include a combination study of its lead asset, Voyager-V1, with avelumab*, a human anti-PD-L1 antibody. But, Vyriad hasn’t disclosed whether the drug target is STING-relevant or not.</p>
</div>
<div id="pipeline" class="section level1">
<h1><strong>Pipeline</strong></h1>
<p><img src="timeline_pic.png" style="width:50%; height:70px"> <img src="company_analysis_excel/vyriad.jpg"></p>
<p>For more details, check the reference below.</p>
</div>
<div id="reference" class="section level1">
<h1>Reference</h1>
<p><a href="http://www.vyriad.com/2016/08/05/vyriad-signs-exclusive-license-agreement-sting-technology-development-enhanced-oncolytic-virotherapy-treatments/" class="uri">http://www.vyriad.com/2016/08/05/vyriad-signs-exclusive-license-agreement-sting-technology-development-enhanced-oncolytic-virotherapy-treatments/</a><br />
<a href="ftp://ftp.puce.edu.ec/facultades/CienciasExactas/Fisica-Quimica/CEN_2018_02_26.pdf" class="uri">ftp://ftp.puce.edu.ec/facultades/CienciasExactas/Fisica-Quimica/CEN_2018_02_26.pdf</a><br />
<a href="https://www.biospace.com/article/biotech-startup-vyriad-graduates-from-mayo-clinic-incubator-to-larger-space-/" class="uri">https://www.biospace.com/article/biotech-startup-vyriad-graduates-from-mayo-clinic-incubator-to-larger-space-/</a> <a href="http://www.vyriad.com/2018/07/18/vyriad-announces-collaboration-merck-kgaa-darmstadt-germany-pfizer-evaluate-oncolytic-virus-voyager-v1-combination-anti-pd-l1-antibody-avelumab-phase-1-clinical-study/" class="uri">http://www.vyriad.com/2018/07/18/vyriad-announces-collaboration-merck-kgaa-darmstadt-germany-pfizer-evaluate-oncolytic-virus-voyager-v1-combination-anti-pd-l1-antibody-avelumab-phase-1-clinical-study/</a></p>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
